Download Compact regs parts 50, 54, 56 and 312 : Code of federal by United States. Food and Drug Administration PDF

By United States. Food and Drug Administration

Show description

Read Online or Download Compact regs parts 50, 54, 56 and 312 : Code of federal regulations 21, parts 50, 54, 56 and 312, good clinical practices PDF

Best clinical books

Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th Edition

The fourth variation of Haddad and Winchester's medical administration of Poisoning and Drug Overdose is the most up-tp-date, authoritative, and concise reference for info regarding the medical administration of kids and adults whose overall healthiness has been effected or in all likelihood effected via poisonous brokers, together with medicinal drugs, environmental threats, and average pollutants.

Hepatitis C Virus Disease: Immunobiology and Clinical Applications

This accomplished quantity, written by way of specialists within the box, emphasizes the newest advances at the Hepatitis C virus an infection (HCV) relocating from uncomplicated study to scientific software. regardless of the varied experiences on HCV an infection, its pathogenesis and clinical therapy haven't been absolutely defined.

Extra info for Compact regs parts 50, 54, 56 and 312 : Code of federal regulations 21, parts 50, 54, 56 and 312, good clinical practices

Example text

5) A clinical investigation involving use of a placebo is exempt from the requirements of this part if the investigation does not otherwise require submission of an IND. 24 of this chapter is not exempt from the requirements of this part. (c) Bioavailability studies. 31. (d) Unlabeled indication. This part does not apply to the use in the practice of medicine for an unlabeled indication of a new drug product approved under part 314 or of a licensed biological product. (e) Guidance. FDA may, on its own initiative, issue guidance on the applicability of this part to particular investigational uses of drugs.

25, be given to the subjects when in the IRB’s judgment the information would meaningfully add to the protection of the rights and welfare of subjects. 24 of this chapter for an exception from informed consent for emergency research are met. (d) In cases where the documentation requirement is waived under paragraph (c)(1) of this section, the IRB may require the investigator to provide subjects with a written statement regarding the research. (e) An IRB shall notify investigators and the institution in writing of its decision to approve or disapprove the proposed research activity, or of modifications required to secure IRB approval of the research activity.

During Phase 1, sufficient information about the drug’s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80. (2) Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes.

Download PDF sample

Rated 4.99 of 5 – based on 4 votes